SLE patient demographic and clinical characteristics at baseline and follow-up
| SLE cohort (n=116) | |
| Age at last visit, median (Q1, Q3) | 46.4 (37.0, 58.1) |
| Age at enrolment, median (Q1, Q3) | 39.5 (31.4, 51.1) |
| Disease duration at enrolment, median (Q1, Q3) | 6.1 (1.4, 12.0) |
| No. of clinic visits, median (Q1, Q3) | 22.5 (15.5, 37.0) |
| Observation period (years), median (Q1, Q3) | 6.7 (4.1, 8.1) |
| Female, n (%) | 102 (87.9) |
| Ethnicity, n (%) | |
| Caucasian | 60 (52.2) |
| Asian | 38 (33.0) |
| Other | 17 (14.8) |
| Medication use during observation period | |
| Prednisolone, n (%) | 93 (80.2) |
| Cumulative prednisolone (mg), median (Q1, Q3) | 7637.5 (918.8, 15 487.5) |
| TAM-prednisolone (mg/day), median (Q1, Q3) | 3.7 (0.5, 7.0) |
| Hydroxychloroquine, n (%) | 110 (94.8) |
| Immunosuppressants*, n (%) | 113 (97.4%) |
| Baseline SLEDAI-2K, median (Q1, Q3) | 4.0 (2.0, 8.0) |
| Baseline SLEDAI-2K >4, n (%) | 48 (41) |
| AMS, median (Q1, Q3) | 3.7 (2.1, 5.2) |
| LLDAS ever attained, n (%) | 109 (94) |
| LLDAS at last review, n (%) | 74 (64) |
| Mild to moderate flare rate (flare/year) | 0.61 |
| Severe flare rate (flare/year) | 0.13 |
| Baseline renal disease†, n (%) | 10 (8.6) |
| BMI (baseline), median (Q1, Q3) | 24.1 (21.9, 27.5) |
| BMI (final), median (Q1, Q3) | 23.5 (21.3, 27.8) |
| Organ damage (baseline) (SDI >0), n (%) | 57 (49.1) |
| Baseline SDI, median (Q1, Q3) | 0.0 (0.0, 1.0) |
| Change in SDI >0, n (%) | 58 (50.0) |
Data are n (%) or median (Q1, Q3).
*Methotrexate, azathioprine, mycophenolate mofetil, mycophenolic acid, leflunomide, ciclosporin, cyclophosphamide, tacrolimus, rituximab or belimumab.
†As captured in baseline SDI (estimated GFR <50%, proteinuria >3.5 g/day or end-stage renal failure).
AMS, time-adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000; BMI, body mass index; GFR, glomerular filtration rate; LLDAS, lupus low disease activity state; SDI, SLICC-ACR Damage Index; SDI, Systemic Lupus International Collaborating Clinics Disease Index; TAM, time-adjusted mean.